切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2024, Vol. 13 ›› Issue (01) : 51 -56. doi: 10.3877/cma.j.issn.2095-3232.2024.01.010

所属专题: 临床研究

临床研究

预后营养指数对交界可切除胰腺癌患者术后预后的预测价值
黄金灿, 王迪, 崔松平, 陈晴, 吕少诚, 贺强, 郎韧()   
  1. 100020 首都医科大学附属北京朝阳医院肝胆外科
  • 收稿日期:2023-10-31 出版日期:2024-02-10
  • 通信作者: 郎韧

Predictive value of prognostic nutritional index for postoperative prognosis in patients with borderline resectable pancreatic cancer

Jincan Huang, Di Wang, Songping Cui, Qing Chen, Shaocheng Lyu, Qiang He, Ren Lang()   

  1. Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China
  • Received:2023-10-31 Published:2024-02-10
  • Corresponding author: Ren Lang
引用本文:

黄金灿, 王迪, 崔松平, 陈晴, 吕少诚, 贺强, 郎韧. 预后营养指数对交界可切除胰腺癌患者术后预后的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(01): 51-56.

Jincan Huang, Di Wang, Songping Cui, Qing Chen, Shaocheng Lyu, Qiang He, Ren Lang. Predictive value of prognostic nutritional index for postoperative prognosis in patients with borderline resectable pancreatic cancer[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(01): 51-56.

目的

探讨预后营养指数(PNI)对交界可切除胰腺癌患者术后预后的预测价值。

方法

回顾性分析2013年3月至2021年12月首都医科大学附属北京朝阳医院行手术治疗的77例交界可切除胰腺癌患者临床资料。患者均签署知情同意书,符合医学伦理学规定。其中男34例,女43例;平均年龄(61±11)岁。根治性胰十二指肠切除术61例,根治性全胰十二指肠切除术16例。根据术前血清ALB和外周血淋巴细胞计数,计算术前PNI为45±5,以45为界值,将患者分为低PNI组(39例)和高PNI组(38例)。生存分析采用Kaplan-Meier法和Log-rank检验,采用Cox多因素分析筛选影响患者远期预后的危险因素。

结果

两组患者均顺利完成手术,术后并发症发生率为30%(23/77)。低PNI组和高PNI组患者中位生存时间分别为8.0、15.5个月,患者术后6个月、1年、2年总体生存率分别为76.7%、40.1%、17.2%和91.8%、65.3%、49.8%,差异有统计学意义(χ2=5.826,P<0.05)。Cox多因素分析显示,低PNI(HR=1.864,95%CI:1.089~3.190,P=0.023)、肿瘤低分化(HR=2.166,95%CI:1.225~3.828,P=0.008)是影响术后远期生存的独立危险因素。

结论

PNI可作为预测交界可切除胰腺癌患者总体生存期的有效指标,低PNI患者预后较差。

Objective

To evaluate the predictive value of prognostic nutritional index (PNI) for prognosis of patients with borderline resectable pancreatic cancer.

Methods

Clinical data of 77 patients with borderline resectable pancreatic cancer who underwent surgical treatment in Beijing Chaoyang Hospital, Capital Medical University from March 2013 to December 2021 were retrospectively analyzed. The informed consents of all patients were obtained and the local ethical committee approval was received. Among them, 34 patients were male and 43 female, aged (61±11) years on average. 61 patients underwent radical pancreaticoduodenectomy and 16 cases of radical total pancreaticoduodenectomy. According to preoperative serum ALB and peripheral blood lymphocyte count, preoperative PNI was calculated as 45±5. All patients were divided into low (n=39) and high PNI groups (n=38) with PNI of 45 as the cut-off value. Survival analysis was performed by Kaplan-Meier analysis and Log-rank test. The risk factors affecting the long-term prognosis of patients were screened by multivariate Cox's model.

Results

All patients successfully completed the surgery. The incidence of postoperative complications was 30%(23/77). The median survival of patients in the low and high PNI groups was 8.0 and 15.5 months. The postoperative 6-month, 1-year and 2-year overall survival rates in two groups were 76.7%, 40.1%, 17.2% and 91.8%, 65.3%, 49.8%, and the differences were statistically significant (χ2=5.826, P<0.05). Multivariate Cox's model showed that low PNI (HR=1.864, 95%CI:1.089-3.190, P=0.023) and low degree of tumor differentiation (HR=2.166, 95%CI:1.225-3.828, P=0.008) were the independent risk factors for postoperative long-term survival.

Conclusions

PNI can be utilized as an effective index to predict the overall survival of patients with borderline resectable pancreatic cancer. Patients with low PNI obtain poor prognosis.

表1 低PNI组和高PNI组交界可切除胰腺癌患者一般资料比较
图1 交界可切除胰腺癌患者术后Kaplan-Meier生存曲线注:PNI为预后营养指数
表2 交界可切除胰腺癌患者术后远期生存的单因素分析
[1]
Khalaf N, El-Serag HB, Abrams HR, et al. Burden of pancreatic cancer: from epidemiology to practice[J]. Clin Gastroenterol Hepatol, 2021, 19(5):876-884.
[2]
Laviano A, Di Lazzaro L, Koverech A. Nutrition support and clinical outcome in advanced cancer patients[J]. Proc Nutr Soc, 2018, 77(4):388-393.
[3]
Ferreira V, Lawson C, Ekmekjian T, et al. Effects of preoperative nutrition and multimodal prehabilitation on functional capacity and postoperative complications in surgical lung cancer patients: a systematic review[J]. Support Care Cancer, 2021, 29(10):5597-5610.
[4]
Okadome K, Baba Y, Yagi T, et al. Prognostic nutritional index, tumor-infiltrating lymphocytes, and prognosis in patients with esophageal cancer[J]. Ann Surg, 2020, 271(4):693-700.
[5]
Zhu X, Zhao Y, Ma F, et al. The role of prognostic nutritional index for clinical outcomes of gastric cancer after total gastrectomy[J]. Sci Rep, 2020, 10(1):17373.
[6]
Zhang J, Xiao X, Wu Y, et al. Prognostic nutritional index as a predictor of diabetic nephropathy progression[J]. Nutrients, 2022, 14(17):3634.
[7]
Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy[J]. Ann Surg Oncol, 2006, 13(8):1035-1046.
[8]
中国抗癌协会胰腺癌专业委员会. 胰腺癌综合诊治指南(2018版)[J]. 临床肝胆病杂志, 2018, 34(10):2109-2120.
[9]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30.
[10]
Poulia KA, Antoniadou D, Sarantis P, et al. Pancreatic cancer prognosis, malnutrition risk, and quality of life: a cross-sectional study[J]. Nutrients, 2022, 14(3):442.
[11]
Lee HS, An C, Hwang HK, et al. Preoperative prediction of futile surgery in patients with radiologically resectable or borderline resectable pancreatic adenocarcinoma[J]. J Gastroenterol Hepatol, 2020, 35(3):499-507.
[12]
Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients[J]. Nihon Geka Gakkai Zasshi, 1984, 85(9):1001-1005.
[13]
Eckart A, Struja T, Kutz A, et al. Relationship of nutritional status, inflammation, and serum albumin levels during acute illness: a prospective study[J]. Am J Med, 2020, 133(6):713-722, e7.
[14]
Fuhrman MP, Charney P, Mueller CM. Hepatic proteins and nutrition assessment[J]. J Am Diet Assoc, 2004, 104(8):1258-1264.
[15]
Hirahara N, Tajima Y, Fujii Y, et al. Preoperative prognostic nutritional index predicts long-term surgical outcomes in patients with esophageal squamous cell carcinoma[J]. World J Surg, 2018, 42(7):2199-2208.
[16]
Rizk EM, Gartrell RD, Barker LW, et al. Prognostic and predictive immunohistochemistry-based biomarkers in cancer and immunotherapy[J]. Hematol Oncol Clin North Am, 2019, 33(2):291-299.
[17]
Ino Y, Yamazaki-Itoh R, Shimada K, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer[J]. Br J Cancer, 2013, 108(4):914-923.
[18]
Lee BM, Byun HK, Seong J. Significance of lymphocyte recovery from treatment-related lymphopenia in locally advanced pancreatic cancer[J]. Radiother Oncol, 2020(151):82-87.
[19]
Kurahara H, Maemura K, Mataki Y, et al. Prognostication by inflammation-based score in patients with locally advanced pancreatic cancer treated with chemoradiotherapy[J]. Pancreatology, 2015, 15(6):688-693.
[20]
Nozoe T, Ninomiya M, Maeda T, et al. Prognostic nutritional index: a tool to predict the biological aggressiveness of gastric carcinoma[J]. Surg Today, 2010, 40(5):440-443.
[21]
de Pinho NB, Martucci RB, Rodrigues VD, et al. Malnutrition associated with nutrition impact symptoms and localization of the disease: results of a multicentric research on oncological nutrition[J]. Clin Nutr, 2019, 38(3):1274-1279.
[22]
Probst P, Haller S, Bruckner T, et al. Prospective trial to evaluate the prognostic value of different nutritional assessment scores in pancreatic surgery (NURIMAS Pancreas)[J]. Br J Surg, 2017, 104(8):1053-1062.
[23]
Reni M, Zanon S, Balzano G, et al. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma[J]. Ann Oncol, 2017, 28(11):2786-2792.
[1] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[6] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[7] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[8] 陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[9] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[10] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[11] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[12] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[13] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要